TAK Stock Analysis: Buy, Sell, or Hold?
TAK - Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
$18.26
0.15 (0.83%)
â˛
5d:
-2.41%
30d:
+4.88%
90d:
+15.06%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Oct 29, 2026
Get Alerted When TAK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: TAK is fairly priced but lacks strong directional signals. At 2.6% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: TAK is fairly priced but lacks strong directional signals. At 2.6% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$36.99
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$22.97
20.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 0.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TAK is currently trading at $18.26, which is considered slightly high relative to its 30-day fair value range of $17.29 to $18.41. The stock's valuation (Forward PE: 0.2) is in line with its historical norms (0.2). At these levels, the market is pricing in 2.6% annual earnings growth.
Technical Outlook: Technically, TAK is in a strong uptrend. The price is currently testing key support at $17.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TAK scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $22.64 (+24.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TAK is in a strong uptrend. The price is currently testing key support at $17.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TAK scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $22.64 (+24.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$17.29 -
$18.41
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
46.2%
All Signals
- BEARISH: Weak technical setup (39/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 24.0% below Wall St target ($22.64)
- BULLISH: Expecting earnings turnaround to 2.6% growth with 10.2% revenue growth
- WARNING: Composite score 50/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$17.29 -
$18.41
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$17.96
Resistance Level
$18.84
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
0.19
Wall Street Target
$22.64
(+24.0%)
Revenue Growth (YoY)
10.2%
Earnings Growth (YoY)
-9.8%
Profit Margin
-3.5%
Valuation Premium vs History
+2.6% premium
PE vs Historical
0.2 vs 0.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.6%
(market-implied from PE analysis)
1-Year Target
$18.73
(+3%)
2-Year Target
$19.22
(+5%)
3-Year Target
$19.72
(+8%)
3-Yr Target (if PE normalizes)
(PE: 0â0)
$20.52
(+12%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 93.0%)
$6465.78
(+35310%)
Base:
(SPY PE: 0.2, Growth: 93.0%)
$61.63
(+238%)
Bear:
(PE: 0.2, Growth: 93.0%)
$52.38
(+187%)
Share & Embed Analysis
Last updated: September 13, 2026 1:15 PM ET
Data refreshes hourly during market hours. Next update: 2:15 PM
Data refreshes hourly during market hours. Next update: 2:15 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TAK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$211 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary ShâĻ |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
